You are here

Investor Relations

Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance

OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.

Currently, we have two candidates in clinical development across multiple oncology therapeutic areas and an additional candidate in pre-clinical development:

Custirsen (OGX-011)

Phase 3 in prostate and lung cancers

OncoGenex's lead compound, custirsen, is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Learn More.

Apatorsen (OGX-427)

Phase 2 in bladder, lung, pancreatic and prostate cancers

Apatorsen (OGX-427) is an investigational drug designed to inhibit the production of heat shock protein (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. Learn More.

*Clusterintelligence™ is a trademark of Teva Pharmaceutical Industries Ltd.

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.